About
Accomplished start-up executive and general manager with a passion for commercialising…
Articles by Daniel
-
Perspectum has been awarded a Horizon2020 grant to show the health economic benefits of non-invasive MRI in diagnosing and staging liver disease
Perspectum has been awarded a Horizon2020 grant to show the health economic benefits of non-invasive MRI in diagnosing and staging liver disease
3 Comments
Activity
3K followers
-
Daniel Green shared thisA fantastic addition to our team, Josh is truly exceptional. I'm looking forward to drawing on his vast experience and insights as we grow mOm !Daniel Green shared thisWe are delighted to announce that Dr Joshua Boger has joined the Board of mOm Incubators. As we accelerate commercial growth, expand into new global markets, and broaden our impact in maternal and neonatal health, we are excited to be joined by Dr Boger, who's guidance will help shape the next chapter of mOm’s journey. With a comprehensive background in pharmaceuticals and healthcare, Dr Boger is the founder of Vertex Pharmaceuticals, retiring as their Chief Executive Officer in May 2009, after over 20-years with the company. Following his tenure as CEO, Dr. Boger continued to to serve on the Vertex Board and Cochaired its Science & Technology Committee, stepping off the board in June 2017, after more than 28 years. Dr. Boger developed an international reputation in the application of computer modeling to the chemistry of drug design and was a pioneer in the use of structure-based rational drug design as the basis for drug discovery programs. While at Vertex he began and championed drug discovery and development programs that brought forth one of the first HIV protease inhibitors, later using the same technology approach to develop the first widely-effective cure for hepatitis C infection, a leading cause of liver cancer and liver failure. A two-decade-long program at Vertex aimed at the fatal genetic disease, cystic fibrosis, has lead to oral combination therapies from Vertex that have been key to increasing the average projected lifespan of afflicted patients from 34 years when the program began to over 65 years today. Dr. Boger has served on numerous boards, including the Harvard Medical School Advisory Board, where he is Chair Emeritus, and he served for almost a decade on the advisory board of Harvard’s Division of Engineering and Applied Sciences. Dr Boger says, "Over the past several years I have watched the team develop mOm from a concept on paper to a fully regulated, life-saving product, medical device now in use across multiple countries. My deep commitment to advancing human health, combined with decades of leadership experience in biotechnology and innovation, will be invaluable as we scale. mOm has the potential to transform the lives of countless children and parents globally. I have dedicated my working life towards improvements in human health, and I am looking forward to doing it again, alongside mOm’s other board members and the impressive, capable team at mOm” Welcome to the team! #mOmIncubators #HealthCareInnovation #biotechnology #neonatalcare #boardmember
-
Daniel Green shared thisIt’s not every day you get the chance to do work that genuinely improves the lives of the most vulnerable. From giving preterm infants in sub‑Saharan Africa a better chance of survival to helping the NHS reduce avoidable NICU admissions and keeping babies with their mothers, it’s hard not to feel inspired by what James Roberts MBE and the team are doing. I’m hugely excited to join mOm Incubators as COO, and to help take this impact to the next level!Daniel Green shared thisCoulter Partners successfully led a search assignment for mOm Incubators Ltd (“mOm”) and is pleased to announce the placement of Daniel Green as Chief Operating Officer (COO). mOm is a pioneering UK-based health-tech company dedicated to transforming neonatal care. Its flagship product, the mOm Essential Incubator, is a world-first, lightweight, and portable device designed to maintain newborn body temperature in any setting – from modern NHS hospitals to humanitarian zones like Ukraine. James Roberts MBE, Founder and CEO of mOm, commented: “The team at Coulter Partners felt like a natural extension of our own hiring team. They were professional, diligent, and took the time to deeply understand our business, our stage of development, and our specific needs. By truly grasping my own role as CEO, they identified high-impact candidates whose strengths are perfectly complementary to mine. Their deep industry knowledge saved us significant time and resulted in a shortlist of exceptional quality.” Read the full press release here: https://lnkd.in/esbdznTs #Innovation #TeamBuilding #ExecutiveSearch #Leadership #TopTalent #Health Key players for this placement: Ian Coyne, Jelena Dukic Grubovic, Joanna Crowle
-
Daniel Green shared thisWe're hiring @ FORG3D for an exceptional software leader - see below.Daniel Green shared this🚀 Big News! Strativ Group Teams Up with Game-Changing Startup! 🚀 We're pumped to announce our exclusive partnership with FORG3D, a mind-blowing DeepTech startup that's about to flip the manufacturing world on its head! 🤯 What makes FORG3D so special? They've mixed robotics, software, and material science like never before Their patented tech is ready to shake up a massive $500bn market They're literally rewriting the rules of metal manufacturing! 🌟 Now, here's where it gets even more exciting... 🌟 We're on the hunt for a Lead Software Developer to join the FORG3D team on this journey! This isn't just any job - it's a chance to: 🔥 Develop their cutting-edge software product 🔥 Be part of a skyrocketing business with advanced tech 🔥 Build your dream team of coding wizards Ready to be part of the next big thing? Don't miss this chance! To apply for the role and find out more follow this link - https://lnkd.in/dTuvTKye #TechRevolution #DreamJob #InnovationNation #FutureOfManufacturing
-
Daniel Green reposted thisDaniel Green reposted thisI'm excited to share that I will be speaking at the ATS Respiratory Innovation Summit this month, which brings together global leaders in respiratory medicine. Chronic respiratory diseases such as Asthma and COPD impact over half a billion people, cost billions in preventable healthcare expenditure and cause millions of deaths worldwide. Using contactless sensors and advanced AI and DSP algorithms, Albus Home can continuously monitor over a dozen nocturnal parameters without patients having to do or wear anything, enabling reliable and objective respiratory monitoring without patient burden. Interested in learning more? DM me or join me at the ATS in San Diego. We also have an exciting announcement coming up - stay tuned! #ATS2024 #RIS2024 #ClinicalTrials #RespiratorySolutions #asthma #copd Michelle Turenne Dustin Bell, PMP
-
Daniel Green shared thisOr.. how not to roll out an update to your medical device. #meddevice #verificationDaniel Green shared thisFurther information regards #Libre2 and #Freestyle #LibreLink App -as it switches to a #CGM via Abbott - and the associated glitches that occurred Apology received & MHRA informed - and hopefully lessons learnt with #Libre3 and #ClosedLoop in the pipeline. Not just for Abbott -but for ALL industry. If you want NHS England to make your tech widely available, ensure all works well...make my life simpler, folks 😀 Information to cascade to those using this device -please do as needed in relevant groups Thank you
-
Daniel Green shared thisGrateful to all at Oxford Academic Health Science Network (Oxford AHSN) for their support & expertise on our exciting #AI project! #asthma #prevention #clinicalevaluationDaniel Green shared thisNEW CASE STUDY: Oxford AHSN is supporting Albus Health with the evaluation of a home monitoring device which uses #AI to predict and prevent #asthma attacks in children. More info: https://lnkd.in/dBxYzM-C
-
Daniel Green shared thisThis is huge! Very encouraging results; let’s see if they can translate this into humans.. #t1d Sana Biotechnology, Inc.Daniel Green shared thisToday we published promising preclinical data in Science Translational Medicine demonstrating that hypoimmune human islet cells normalized glucose in a diabetic humanized immunocompetent mouse model and avoided allogeneic and autoimmune rejection by the immune system. With hypoimmune pancreatic islet cell therapy, we have the potential to control blood glucose without immunosuppression and exogenous insulin administration. We are excited by the possibility of potentially transforming the treatment landscape for diabetes patients. Learn more here: https://lnkd.in/gRNbRsKxSana Biotechnology Announces Preclinical Data Published in Science Translational Medicine Showing its Hypoimmune Pancreatic Islet Cells Evaded Allogeneic and Autoimmune Rejection and Controlled Type 1 Diabetes in Preclinical Model | Sana Biotechnology, IncSana Biotechnology Announces Preclinical Data Published in Science Translational Medicine Showing its Hypoimmune Pancreatic Islet Cells Evaded Allogeneic and Autoimmune Rejection and Controlled Type 1 Diabetes in Preclinical Model | Sana Biotechnology, Inc
-
Daniel Green shared thisEarly days, but an exciting development towards a functional cure for #t1d !Daniel Green shared thisWe’ve announced clinical trial clearances from both the FDA and Health Canada for our investigational encapsulated cell therapy for the potential treatment of type 1 diabetes. With this step forward, we plan to initiate clinical trials for this approach later this year. Learn more: vrtx.com
-
Daniel Green shared thisDaniel Green shared thisAround 8 million people in the UK have been diagnosed with #asthma. The disease is the most chronic disease in children and many continue to suffer the symptoms into adulthood. As a condition, asthma is usually mild, but sufferers often require monitoring to ensure that symptoms don’t get worse. A new device - the Albus Home RD - makes it easier to monitor asthma symptoms during the night. By monitoring a child’s breathing, the device detects patterns and provides valuable information to clinicians. Read on to see how Albus Health – makers of the device and a KHP Ventures portfolio company – is working with Birmingham Women's and Children's NHS Foundation Trust and other partners to predict and prevent asthma attacks ⬇ https://lnkd.in/enH3p6ec #digitalhealth #healthtech #healthcare #FromConceptToCare
Daniel Green commented on a post
4d
All the best, Rick - enjoy retirement!
Daniel Green commented on a post
1mo
Huge congratulations James Davis Charalambos Antoniades MD PhD FRCP FMedSci and the whole team - a worthy and important achievement!
-
Daniel Green liked thisDaniel Green liked thisClinical trials have advanced in what they measure, yet a large proportion of disease activity still occurs outside of the clinic and outside traditional measurement windows. In International Clinical Trials, our CEO Mikesh Udani explores how continuous, passive monitoring is ripe to close this gap. The article highlights how passive, contactless technologies are now clinically validated and operationally ready for global trials, enabling objective nighttime data without burdening patients or sites. This opens opportunities for more sensitive endpoints to detect exacerbations, accurately measure symptom resolution, and monitor patient safety. Nighttime symptoms, sleep-related biomarkers and overnight deterioration are clinically relevant across asthma, COPD, heart failure and neurological conditions but remain difficult to capture with traditional tools. Access the full article here to explore the data, validation studies and operational considerations. https://lnkd.in/eDauDshT Albus Health Yasmin Nolan #ClinicalTrials #DigitalEndpoints #ContinuousMonitoring #NighttimeData #HealthTech
-
Daniel Green liked thisIt was a pleasure to speak with Entrepreneur UK about our journey with Brainomix starting as a spin-out from Oxford University to an international healthcare AI company and what it takes to scale AI in healthcare from promise to proof. Thank you to Entrepreneur UK for the opportunity to reflect on some of the lessons from the Brainomix journey so far. #AIinHealthcare #HealthTech #EvidenceBasedMedicine #Entrepreneurship #BrainomixDaniel Green liked thisWhat does it take to turn an AI idea into a lasting healthcare business? For Michalis Papadakis, CEO and Co-Founder of Brainomix, it starts with purpose, evidence and the ability to adapt. Brainomix was built around a real clinical need, using AI as a tool to help clinicians make faster, more informed decisions — not as an end in itself. In the latest Entrepreneur UK article, Papadakis shares lessons from taking Brainomix from an Oxford research project to an international health technology company, including why scientific evidence, user trust and understanding the wider healthcare system are essential to scaling innovation. A valuable read for founders building at the intersection of technology, healthcare and impact. Read the full article: https://lnkd.in/gQRWC_52 #EntrepreneurUK #Entrepreneurship #AI #HealthTech #HealthcareInnovation #ArtificialIntelligence #Startups #Leadership #Innovation #Brainomix
-
Daniel Green reacted on thisDaniel Green reacted on this#retirement, #pension #timeoff Dear friends, colleagues, After 40 years and 2 weeks it is time. As off August 2026 I commenced my early retirement to enjoy life and make place for the next generation. Starting in 1986 with a team of 14 in total, we took upon us all challeges that came by. Building the first half scale shielded gradientcoil for Philips Netherlands, followed by multiple models of MRI gradient coils, resulting in being a valued supplier towards the MRI industry, never believing we would grow to a company of >100. It has been my privilege to have been working with you all in good times and also in the less good times. Challenges come in different variaties. Together we have always found solutions as a team and this made us all grow. I will be enjoying life with family and friends, never a dull moment. Wishing you all a very nice future and good health, again, thanks for the past years, its been a blast. Rick
-
Daniel Green reacted on thisDaniel Green reacted on thisAnd just like that? 3 months ago …today…everything changed The beeps of the machines on an ITU The quietness as the life support machine stopped..the decision made early that morning The desperate ask to the medical team “Have we done everything” The warmth of hands …one last time as the beeps slowed. The feeling of a life slipping away… 3 months And there hasn’t been a day when I haven’t felt lost. And not hurting. I am trying. The urge to do nothing but sit is overwhelming- grief can be like a suffocation. Yet one has to stand up too - and the love & support from many has helped. Thank you for that to so many x
-
Daniel Green reacted on thisDaniel Green reacted on thisExcited to share that I have received an NIH/NHLBI #K23 Career Development Award for the project "TARGET-TTR: Targeted AI-Driven Screening of ATTR-CM in the EHR". Building on our TARGET-AI framework (https://lnkd.in/gM2c4Pbf), this work will integrate longitudinal EHR phenotypes with AI-ECG and AI-Echo to determine whom to screen, when to screen, and how to best translate algorithmic signals into a scalable diagnostic pathway for ATTR-CM. Deeply grateful to Rohan Khera, as well as Cynthia Brandt, Hua Xu, Edward Miller, Eric J. Velazquez and many more for their mentorship, and to Yale School of Medicine for providing the collaborative environment that makes this work possible. Looking forward to expanding this program with our outstanding team and collaborators. #AI #Cardiology #CardiacAmyloidosis #ATTR Yale Department of Internal Medicine Yale University Cardiovascular Data Science (CarDS) Lab
-
Daniel Green liked thisDaniel Green liked thisAround 10% of babies are born preterm globally. More than a million die every single year and many more survive but face lifelong complications, all because of challenges that, in many cases, come down to simple, solvable issues, such as maintain normothermia. For a premature baby, staying within what’s called the thermal neutral zone is critical. It’s the point where they can use their energy to grow, rather than simply trying to stay warm. Small changes really matter. As soon as they become hypothermic, the risks escalate fast. For every 1°C drop in core body temperature, a baby’s mortality increases by around 28%. One of the most effective ways to protect these babies is with incubators but traditional systems , whose design has remained relatively unchanged for decades, are often heavy, not cost effective, impractical for certain situations, and inaccessible for many parts of the world, or in a hospital That’s why we built the mOm Essential. To solve these key challenges and help save more lives. Today, we estimate mOm Incubators have already impacted around 18,000 lives, helping babies in hospitals, such as in the NHS, clinics and conflict zones around the world, stay warm when it matters most. Please reach out to myself or the team to arrange a demo or learn more about out how we, and the mOm system, work with healthcare providers globally. Stuart C. Joanne Hanson-Halliwell Richard Marlow Clive Dean #neonatal #maternity #warmthwithoutescalation
-
Daniel Green liked thisDaniel Green liked thisWe can predict cancer therapy-related cardiac dysfunction from an ECG taken before treatment starts. In patients starting BRAF/MEK inhibitors for melanoma, adding AI-ECG to the guideline HFA-ICOS risk score significantly improved prediction of moderate/severe cardiotoxicity (C-statistic 0.81 to 0.91, p = 0.030). Small cohort and few events, so it needs replication. But a test performed everywhere, at a very low cost, could help direct cardiac surveillance towards the patients most likely to need it. Grateful to Claire Glen, Ninian Lang, Iain Squire and the Glasgow cardio-oncology team, and to my supervisors Fu Siong Ng and Arunashis Sau. Open-access paper linked in the comments. #CardioOncology #Cardiology #ArtificialIntelligence #AIECG #Cardiotoxicity #ClinicalResearch #DigitalHealth #NewPaper
-
Daniel Green liked thisDaniel Green liked thisWe spent time with James Roberts MBE, Daniel Green, and Gemma Singer from mOm Incubators to talk about what it really takes to manufacture a critical medical device that has to work anywhere, from NHS wards to conflict zones. Watch our case study to see Cogent Technology's role in the mOm Essential Incubator! #CogentTechnology #HeathpatchGroup #MedTech #Maternity #Neonatal
Experience & Education
Licenses & Certifications
-
PRINCE2 Foundation in project management
AXELOS Global Best Practice
IssuedCredential ID SA32024722 -
PRINCE2 Practitioner certificate in project management
AXELOS Global Best Practice
Issued ExpiresCredential ID BP32024975
Organizations
-
ISMRM: International Society of Magnetic Resonance in Medicine
Full Member
- Present
Other similar profiles
Explore more posts
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore More